Bimekizumab Durability of High-Level Clinical and Quality of Life Responses in Early Responders with Moderate to Severe Plaque Psoriasis: 4-Year Results from Four Phase 3 Trials. J of Skin. 2026;10(3):s773. doi:10.25251/h6t2hj68